2025-04-10 - Analysis Report
## Natera Inc. (NTRA) Stock Report

**0. Key Figures & Initial Analysis:**

Natera Inc. is a company focused on providing genetic testing services.  The provided data shows significant outperformance relative to the S&P 500 (VOO), but with considerable volatility.

**1. Performance Comparison & Divergence:**

* **NTRA Cumulative Return:** 130.06%
* **VOO Cumulative Return:** 62.61%
* **Return Difference:** 67.4%  This indicates NTRA significantly outperformed VOO. The relative divergence of 16.0% suggests that while NTRA's outperformance is substantial, it falls within the middle range of historical relative performance compared to the S&P 500.  The high maximum divergence (629.5%) and low minimum (-39.4%) suggest periods of extreme outperformance and underperformance.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -6.0% | 62.4% | -0.1 | 1.2 |       |
| 2016-2018  | 29.0% | 80.1% | 0.2 | 1.9 |       |
| 2017-2019  | 159.0% | 80.1% | 0.9 | 4.5 |       |
| 2018-2020  | 530.0% | 80.1% | 0.4 | 13.4 |       |
| 2019-2021  | 355.0% | 62.9% | 0.2 | 12.6 |       |
| 2020-2022  | -119.0% | 62.9% | 0.2 | 5.4 |       |
| 2021-2023  | -482.0% | 69.9% | 1.1 | 8.5 |       |
| 2022-2024  | -75.0% | 70.6% | 1.2 | 21.4 |       |
| 2023-2025  | 79.0% | 78.1% | 0.8 | 20.5 |       |

The table shows highly volatile performance with periods of significant outperformance (e.g., 2018-2020) and substantial underperformance (e.g., 2021-2023).  Beta fluctuates significantly, suggesting sensitivity to market movements changes over time.  Alpha is positive in several periods, implying outperformance beyond market expectations.  Market capitalization (Cap) also shows significant growth and fluctuation.

**2. Recent Price Movement:**

* **Closing Price:** $151.97
* **5-day Moving Average:** $139.01
* **20-day Moving Average:** $145.44
* **60-day Moving Average:** $157.19

The price is above the 5-day and 20-day moving averages, suggesting a short-term uptrend. However, it's below the 60-day moving average, indicating potential resistance at higher levels.  The recent price change of $14.93 represents a significant jump from the previous close.

**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.5289 (High Risk)  This suggests a relatively high level of risk associated with the stock.
* **RSI:** 51.92 (Slightly above neutral)  This indicates neither overbought nor oversold conditions.
* **PPO:** 0.15  A positive PPO suggests bullish momentum.
* **Relative Divergence Change (20-day):** +0.4 (Short-term uptrend)
* **Expected Return (2+ years):** 156.1% This represents a significantly higher expected return than the S&P 500 over the long term. The sharp price increase (`{'price': 151.97, 'previousClose': 132.23, 'change': 14.93}`) indicates a recent sharp upturn.


**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue      |
|------------|---------|--------------|
| 2024-11-12 | -$0.26  | $0.44B       |
| 2024-08-09 | -$0.30  | $0.41B       |
| 2024-05-10 | -$0.56  | $0.37B       |
| 2023-11-09 | -$0.95  | $0.27B       |
| 2024-11-12 | -$0.95  | $0.27B       |

There's a noticeable inconsistency in the data (two entries for 2024-11-12).  Regardless, the company shows consistent negative EPS, although revenue is growing.  Further investigation is needed to understand the reasons behind the negative profitability.  The reported revenue may not be reliable without reconciliation between the two entries.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.48B | 62.94%       |
| 2024-09-30 | $0.44B | 61.79%       |
| 2024-06-30 | $0.41B | 58.83%       |
| 2024-03-31 | $0.37B | 56.72%       |
| 2023-12-31 | $0.31B | 51.38%       |

Revenue shows a clear upward trend.  Profit margins are high but need to be analyzed in conjunction with the negative EPS.  The discrepancy between high margins and negative earnings requires further investigation into cost structure and accounting practices.

**Capital and Profitability:**

| Quarter | Equity | ROE    |
|---------|---------|--------|
| 2024-12-31 | $1.20B | -4.50% |
| 2024-09-30 | $0.88B | -3.60% |
| 2024-06-30 | $0.84B | -4.48% |
| 2024-03-31 | $0.79B | -8.51% |
| 2023-12-31 | $0.77B | -10.20% |

Negative ROE across all quarters raises serious concerns about the company's profitability and efficiency in utilizing shareholder equity. This needs further investigation.


**6. Overall Analysis:**

NTRA has shown periods of remarkable outperformance against the S&P 500, but this is coupled with extreme volatility and consistently negative EPS despite high profit margins. Recent price action shows a sharp upward move, but technical indicators suggest a high-risk environment.  The negative ROE is a significant red flag.  Before considering investment, a thorough analysis of the reasons behind the negative earnings, the discrepancy in reported data, and the sustainability of revenue growth is crucial.  The high expected return is promising but must be weighed against the significant risks involved.  Further due diligence, including a deep dive into the company's financials and business model, is strongly recommended.
